My research aims to improve efficacy, accessibility, and availability of addiction treatments and HIV risk reduction and prevention interventions in diverse settings and populations. My recent work focuses on the development of behavioral counseling programs that target high-risk individuals; addressing their limited understanding of addiction problems and treatment process, increasing their treatment engagement, helping them to transfer treatment-learned skills into real-life situations, and reducing their risks of HIV and other infectious diseases.
Extensive Research Description
My primary research interest is in developing novel treatment interventions for patients with substance abuse disorders, in particular opiate-dependent individuals. I am involved in multiple international research efforts to improve substance abuse treatments, with emphasis on culturally appropriate evidence-based treatments. My teaching and educational efforts are focused on training therapists, drug counselors, and other medical and non-medical personnel in providing behaviorally oriented psychosocial interventions for patients receiving agonist maintenance treatments, or other forms of pharmacological and drug-free treatments for opiate dependence.
I am currently the principal investigator on two collaborative international studies:
A study entitled "Behavioral Drug and HIV Risk Reduction Counseling with MMT in China" will provide critical data regarding the efficacy for reducing drug-and sex-related HIV transmission risk behaviors, as well as improving MMT outcomes and patient functioning of two transportable counseling models, behavioral drug and HIV risk reduction counseling (BDRC) and educational counseling (EC) as compared with the current standard of care model in MMT in China. Supported by NIDA/NIH grant R01 DA026797.
A study entitled "Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia" will examine the effects of combining behavioral therapy with naltrexone pharmacotherapy for the treatment of opiate dependence and reduction of HIV risks in opiate dependent individuals in St. Petersburg, Russia. Supported by NIDA/NIH grant R01 DA 27405.
- Deng, Q., Tang, Q, Schottenfeld, R.S., Hao, W., Chawarski, M.C. (in press). Drug use in rural China: A preliminary investigation in Hunan Province. Addiction.
- Chawarski, M.C., Zhou, W., Schottenfeld, R.S. (2011). Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial. Drug and Alcohol Dependence, 115, 237–239.
- Vicknasingam, B., Mazlan, M., Schottenfeld, R.S., and Chawarski, M.C. (2010). Injection of Buprenorphine and Buprenorphine/Naloxone Tablets in Malaysia. Drug and Alcohol Dependence, 111, 44-49.
- Chawarski, M.C., Mazlan, M., & Schottenfeld, R.S. (2008). Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial. Drug and Alcohol Dependence, 94, 281–284.
- Schottenfeld, R.S., Chawarski, M.C., & Mazlan, M. (2008). Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomized double-blind placebo-controlled trial. The Lancet, 371, 2192-2200.
- Fiellin, D.A., Moore, B.A., Sullivan, L.E., Becker, W.C., Pantalon, M.V., Chawarski, M.C., Barry, D.T., O'Connor, P.G., & Schottenfeld, R.S. (2008). Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. The American Jou
- Chawarski, M.C., Fiellin, D.A., O’Connor, P.G., Bernard, M. & Schottenfeld, R.S. (2007). Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. Journal of Substance Abuse Treatment, 33, 411-5.
- Chawarski, M.C., Mazlan, M., & Schottenfeld, R.S. (2006). Heroin dependence and HIV infection in Malaysia. Drug and Alcohol Dependence, 82 (Suppl. 1), 39-42.
- Fiellin, D.A., Pantalon, M.V., Chawarski, M., Moore, B.A., Sullivan, L.E., O'Connor, P.G., & Schottenfeld, R. (2006). Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine, 355(4): 365-374.
- Chawarski, M.C., Moody, D.E., Pakes, J., O’Connor, P.G., & Schottenfeld, R.S. (2005). Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy and symptoms. Journal of Substance Abuse Treatment, 29, 307-312.
- Chawarski, M.C., Schottenfeld, R.S., O’Connor, P.G., & Pakes, J. (1999). Plasma concentration of buprenorphine at 24- to 72-hour intervals after the administration. Drug and Alcohol Dependence, 55(1-2), 157-163.
- Chawarski, M.C., Pakes, J., & Schottenfeld, R.S. (1998). Assessment of HIV risk. Journal of Addictive Diseases, 17(4), p. 49-59, and in: E. Gottheil and B. Stimmel (Eds.) Effects of Substance Abuse Treatment on AIDS Risk Behaviors. The Haworth Press,